ALX starts Phase II trial of colorectal cancer combo therapy
The investigator-sponsored, open-label, single-arm, multicentre trial is being managed by contract research organisation Criterium.
Oncology
Latest in
Oncology
Greenwich begins Phase III trial of immunotherapy for breast cancer
The trial will assess the safety and efficacy of GLSI-100 in patients with HER2/neu positive breast cancer.
Gamida doses first subject in Phase I/II cell therapy trial for lymphomas
The Phase II expansion portion of the trial will assess GDA-201’s safety and efficacy in two cohorts of 63 subjects.
Peel Therapeutics begins Phase I solid tumour trial
The trial will assess the safety, tolerability, pharmacokinetics and initial antitumor activity of PEEL-224.
Novel checkpoint inhibitors hit by another setback, but opportunities remain
A trial of novel checkpoint inhibitor monalizumab has been terminated after the drug failed to meet the efficacy threshold.
By
BeiGene reports Phase III tislelizumab data in hepatocellular cancer
Tislelizumab’s safety profile was in line with prior trials without any new safety signals observed.
Sapience to begin sub-study of Phase I-II glioblastoma trial
Determining ST101’s penetration in the brain and its link with plasma levels are the secondary objectives of the trial.
Pipeline Moves: Novartis Phase I/Ib cancer trial terminates, further study chances drop
The Clinical Trials Arena team also investigate assets in radiculopathy, solid tumours, radicular pain, autoimmune disorders and inflammation.
By